These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 27090944)
41. Histone deacetylase inhibitor-induced emergence of synaptic δ-opioid receptors and behavioral antinociception in persistent neuropathic pain. Tao W; Zhou W; Wang Y; Sun T; Wang H; Zhang Z; Jin Y Neuroscience; 2016 Dec; 339():54-63. PubMed ID: 27646288 [TBL] [Abstract][Full Text] [Related]
42. Epigenetic therapy of cancer with histone deacetylase inhibitors. Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724 [TBL] [Abstract][Full Text] [Related]
43. Histone deacetylases in cardiac fibrosis: current perspectives for therapy. Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371 [TBL] [Abstract][Full Text] [Related]
44. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. Zafar SF; Nagaraju GP; El-Rayes B Expert Opin Ther Targets; 2012 Jul; 16(7):707-18. PubMed ID: 22621256 [TBL] [Abstract][Full Text] [Related]
45. Development and therapeutic impact of HDAC6-selective inhibitors. Dallavalle S; Pisano C; Zunino F Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920 [TBL] [Abstract][Full Text] [Related]
46. The biology and therapeutic implications of HDACs in the heart. McKinsey TA Handb Exp Pharmacol; 2011; 206():57-78. PubMed ID: 21879446 [TBL] [Abstract][Full Text] [Related]
47. Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes. Sharma S; Taliyan R Pharmacol Res; 2016 Nov; 113(Pt A):320-326. PubMed ID: 27620069 [TBL] [Abstract][Full Text] [Related]
48. Development of histone deacetylase inhibitors for cancer treatment. Marchion D; Münster P Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177 [TBL] [Abstract][Full Text] [Related]
53. [Histone deacetylase inhibitors as therapeutic agents for polyglutamine disorders]. Jiang H; Jia D; Tang B Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):52-5. PubMed ID: 20140868 [TBL] [Abstract][Full Text] [Related]
54. Therapeutic effects of histone deacetylase inhibitors on kidney disease. Chun P Arch Pharm Res; 2018 Feb; 41(2):162-183. PubMed ID: 29230688 [TBL] [Abstract][Full Text] [Related]
55. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target? Petta V; Gkiozos I; Strimpakos A; Syrigos K Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844 [TBL] [Abstract][Full Text] [Related]
56. [Histone modification and its application in therapy for hematologic malignancies -- review]. Fang MH; Ji XM Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):816-20. PubMed ID: 19549415 [TBL] [Abstract][Full Text] [Related]
57. Towards histone deacetylase inhibitors as new antimalarial drugs. Andrews KT; Tran TN; Fairlie DP Curr Pharm Des; 2012; 18(24):3467-79. PubMed ID: 22607140 [TBL] [Abstract][Full Text] [Related]
58. The role of HDACs inhibitors in childhood and adolescence acute leukemias. Masetti R; Serravalle S; Biagi C; Pession A J Biomed Biotechnol; 2011; 2011():148046. PubMed ID: 21318168 [TBL] [Abstract][Full Text] [Related]
59. Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis. Zhou B; Margariti A; Zeng L; Xu Q Cardiovasc Res; 2011 Jun; 90(3):413-20. PubMed ID: 21233251 [TBL] [Abstract][Full Text] [Related]